In The Spotlight
DDNews Cancer Research Exclusive
 
 
Recent work with nanoparticles offers a new approach to photo-thermal cancer therapies
 
(Photo credit: University of Toronto)
 
The PEARLs (Photothermal Enhancing Auto-Regulated Liposomes) were developed by Dr. Gang Zheng of the Princess Margaret Cancer Centre and University of Toronto and colleagues, who say they overcome traditional roadblocks to penetrate deeper into tumors.
 
 
NEWS
A roundup of recent preclinical cancer research
 
Progenics shares data supporting imaging analysis technology in prostate cancer
 
Evidence shows patients benefit from molecular profiling
 
Shuwen Biotech Co. Ltd. and Bliss Biopharmaceutical Co. Ltd. have teamed up in a partnership agreement
 
An exclusive collaboration and license agreement is underway between Agios Pharmaceuticals Inc. and CStone Pharmaceuticals to develop and commercialize Agios’ ivosidenib
 
Biotargeting system aims to drive clinical trial success in cancer studies
 
Findings published in Cancer Cell; company’s next-generation anti-CTLA-4 antibody slated for IND in 2018
 
Along with this comes the initiation of CMC development of platform assets
 
  
FEATURES
(Photo credit: NCI, NIH)
 
 
The latest Annual Report to the Nation shares that cancer survival rates are rising, while incidence and death rates are on a downward trend
 
OPINION
CAR-T Next Generation Immunotherapy: Better Targeting, New Approaches
by Dr. Eyal Talor, CEL-SCI
A look at what to expect from the second generation of cancer immunotherapies, after the progress--and pitfalls--of CAR-T cell therapies

Guest Commentary: Planning successful oncology trials amid a rapidly shifting treatment landscape
by JK Bryan & A Zupnick, Novella
When it comes to oncology clinical trials, drug developers need to stay abreast of the rapidly evolving and competitive landscape while also remaining flexible and innovative in responding to these changes

Enhancing Immuno-Oncology with RNA Interference
by Dr. Alexey Eliseev, RXi
The “War on Cancer” declared by the National Cancer Act of 1971 proceeded through a series of evolutionary developments in chemotherapy, radiation treatments and targeted therapies, but until recently was only marginally successful in extending the lives of late-stage cancer patients. A major breakthrough has been achieved over the last decade with the development of immunotherapeutic treatments that empower a patient’s own immune cells to destroy tumors

 
CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.